Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2913-2921

  Mason, Jay W ^a,b   Selness, Daniel S ^b   Moon, Thomas E ^b   O'Mahony, Bridget ^c,d   Donachie, Peter ^c   Howell, Julian ^c  

^a UNIVERSITY OF UTAH   (United States)

^b Spaulding Clinical Research LLC ^*  (United States)

^c ProStrakan Pharmaceuticals Ltd   (United Kingdom)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; MOXIFLOXACIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AZA COMPOUNDS; ELECTROCARDIOGRAPHY; FEMALE; GRANISETRON; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; QUINOLINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84861148361     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2785     Document Type: Article

References (26)

1. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18:163-73. (Pubitemid 30118410) (Pubitemid 30118410)
2. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist 2004;9:673-86. (Pubitemid 39546407) (Pubitemid 39546407)
3. International Conference on Harmonisation (ICH). Guidance for industry: E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. [updated 2005 Oct; cited 2011 Jul 13]. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm129357.pdf.
4. 3 receptor antagonists. Ann Pharmacother 2003;37:1276-86.
5. Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern? Oncologist 2002;7:65-72. (Pubitemid 34151109) (Pubitemid 34151109)
6. Anzemet® injection (dolesetron mesylate) [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2011.
7. Anzemet® tablets (dolasetron mesylate) [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2011.
8. Zofran® (ondansetron hydrochloride) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.
9. Zofran® (ondansetron hydrochloride) injection for intravenous use [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
10. Kytril (granisetron hydrochloride) injection, for intravenous use [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2011.
11. Kytril (granisetron hydrochloride) tablets [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2010.
12. Aloxi® (palonsetron HCl) injection for intravenous use [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2009.
13. Sancuso (granisetron transdermal system) [package insert]. Bedminster, NJ: ProStrakan, Inc.; 2008.
14. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2009;15:223-31.
15. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19:1609-17.
16. Center for Drug Evaluation and Research, Office of New Drugs. Manual of policies and procedures, interdisciplinary review team forQTstudies [MAPP 6020.14]. [updated 2007 Oct 16; cited 2011 Aug 18]. Available from: http://www.icardiac.com/downloads/QT%20IRT%20MAPP%206020.14.pdf.
17. Fridericia LS. The duration of systole in an electrocardiogramin normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 2003;8:343-51. (Pubitemid 38569971) (Pubitemid 38569971)
18. Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat 2008;18:451-67. (Pubitemid 351891689)
19. FDA Drug Safety Communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). [updated 2010 Dec 17; cited 2011 Apr 7]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.
20. Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005;28:201-4.
21. Carmichael J, Harris AL. High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs 2003;14:739-44. (Pubitemid 37357699)
22. Corrigan BW, Nicholls B, Thakrar B, Lam R, Grosse C, Alianti J, et al. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos 1999;27:110-2. (Pubitemid 29061009) (Pubitemid 29061009)
23. Cupissol D, Bressolle F, Adenis L, Carmichael J, Bessell E, Allen A, et al. Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharm Sci 1993;82:1281-4. (Pubitemid 23354153) (Pubitemid 23354153)
24. Upward JW, Arnold BD, Link C, Pierce DM, Allen A, Tasker TC. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer 1990;26 Suppl 1:S12-5. (Pubitemid 20255642) (Pubitemid 20255642)
25. Roden DM, Yang T. Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation 2005;112:1376-8. (Pubitemid 41291759) (Pubitemid 41291759)
26. Howell J, Mason JW, O'Mahony B, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting [abstract]. In: Proceedings of the MASCC/ISOO Annual International Symposium; 2011 Jun 23-25; Athens, Greece.